251 related articles for article (PubMed ID: 34538873)
1. Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney.
Kapur P; Gao M; Zhong H; Chintalapati S; Mitui M; Barnes SD; Zhou Q; Miyata J; Carrillo D; Malladi VS; Rakheja D; Pedrosa I; Xu L; Kinch L; Brugarolas J
Mod Pathol; 2022 Mar; 35(3):333-343. PubMed ID: 34538873
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological features of low-grade oncocytic renal tumor (CD117-negative, cytokeratin 7-positive): report of seven cases].
Xie B; Cheng LC; Yin GL; Liu BA; Hu ZL; Tong K
Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):719-725. PubMed ID: 35922161
[No Abstract] [Full Text] [Related]
3. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY
Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634
[TBL] [Abstract][Full Text] [Related]
4. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1.
Morini A; Drossart T; Timsit MO; Sibony M; Vasiliu V; Gimenez-Roqueplo AP; Favier J; Badoual C; Mejean A; Burnichon N; Verkarre V
Mod Pathol; 2022 Mar; 35(3):352-360. PubMed ID: 34531523
[TBL] [Abstract][Full Text] [Related]
5. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
[TBL] [Abstract][Full Text] [Related]
6. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
[TBL] [Abstract][Full Text] [Related]
7. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.
Farcaş M; Gatalica Z; Trpkov K; Swensen J; Zhou M; Alaghehbandan R; Williamson SR; Magi-Galluzzi C; Gill AJ; Tretiakova M; Lopez JI; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Siadat F; Sangoi A; Gao Y; Ptákova N; Kuthi L; Pivovarcikova K; Rogala J; Agaimy A; Hartmann A; Fraune C; Rychly B; Hurnik P; Durcansky D; Bonert M; Gakis G; Michal M; Hora M; Hes O
Mod Pathol; 2022 Mar; 35(3):344-351. PubMed ID: 34521993
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT.
Ricci C; Ambrosi F; Franceschini T; Giunchi F; Grillini A; Franchini E; Grillini M; Schiavina R; Massari F; Mollica V; Tateo V; Bianchi FM; Bianchi L; Droghetti M; Maloberti T; Tallini G; Colecchia M; Acosta AM; Lobo J; Trpkov K; Fiorentino M; de Biase D
Virchows Arch; 2023 Nov; 483(5):687-698. PubMed ID: 37845471
[TBL] [Abstract][Full Text] [Related]
9. Low-grade oncocytic tumour (LOT) of the kidney is characterised by GATA3 positivity, FOXI1 negativity and mTOR pathway mutations.
Chen T; Peng Y; Lei T; Wu C; Wang H; Shi Y
Pathol Oncol Res; 2023; 29():1610852. PubMed ID: 36816543
[No Abstract] [Full Text] [Related]
10. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
Tjota MY; Wanjari P; Segal J; Antic T
Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
[TBL] [Abstract][Full Text] [Related]
11. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
12. Low-grade oncocytic tumor (LOT) - a new renal entity ready for a prime time: An updated review.
Mansoor M; Siadat F; Trpkov K
Histol Histopathol; 2022 May; 37(5):405-413. PubMed ID: 35156688
[TBL] [Abstract][Full Text] [Related]
13. Low grade oncocytic renal tumor (LOT): Clinicopathological characterization of 13 cases.
Almutairi F; Xu B
Pathol Res Pract; 2024 Feb; 254():155127. PubMed ID: 38241777
[TBL] [Abstract][Full Text] [Related]
14. Concordance of MTOR Pathway Mutations and the Diagnosis of Renal Low-Grade Oncocytic Tumor (LOT).
Siegmund SE; Al-Obaidy KI; Tsai HK; Idrees MT; Akgul M; Acosta AM; Hirsch MS
Int J Surg Pathol; 2024 Apr; 32(2):316-330. PubMed ID: 37357748
[TBL] [Abstract][Full Text] [Related]
15. Do we need an updated classification of oncocytic renal tumors? : Emergence of low-grade oncocytic tumor (LOT) and eosinophilic vacuolated tumor (EVT) as novel renal entities.
Hes O; Trpkov K
Mod Pathol; 2022 Sep; 35(9):1140-1150. PubMed ID: 35273336
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
[TBL] [Abstract][Full Text] [Related]
17. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases.
Petersson F; Gatalica Z; Grossmann P; Perez Montiel MD; Alvarado Cabrero I; Bulimbasic S; Swatek A; Straka L; Tichy T; Hora M; Kuroda N; Legendre B; Michal M; Hes O
Virchows Arch; 2010 Apr; 456(4):355-65. PubMed ID: 20300772
[TBL] [Abstract][Full Text] [Related]
18. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma.
Ruiz-Cordero R; Rao P; Li L; Qi Y; Atherton D; Peng B; Singh RR; Kim TB; Kawakami F; Routbort MJ; Alouch N; Chow CB; Tang X; Lu W; Brimo F; Matin SF; Wood CG; Tannir NM; Wistuba II; Chen K; Wang J; Medeiros LJ; Karam JA; Tamboli P; Sircar K
Mod Pathol; 2019 Nov; 32(11):1698-1707. PubMed ID: 31231128
[TBL] [Abstract][Full Text] [Related]
19. [CK7+/CD117- low grade oncocytic tumor of the kidney: a clinicopathological analysis].
Bai YF; Chang CD; Wang B; Zhao M; Teng XD
Zhonghua Bing Li Xue Za Zhi; 2022 Oct; 51(10):976-980. PubMed ID: 36207909
[No Abstract] [Full Text] [Related]
20. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]